Browse Articles

Investigating Lymphocytic Involvement in Minimal Change Nephrotic Syndrome

Muncan et al. | Jan 27, 2016

Investigating Lymphocytic Involvement in Minimal Change Nephrotic Syndrome

Minimal Change Disease (MCD) is a degenerative kidney disease. Researchers know very little about the cause of this disorder, however some research has suggested that T lymphocytes may be involved. In this study, the authors measure CD4 and CD8 T cell subpopulations in patients with MCD to investigate whether irregular T lymphocyte populations may be involved in MCD pathogenesis.

Read More...

Reactivity-informed design, synthesis, and Michael addition kinetics of C-ring andrographolide analogs

Zhou et al. | Nov 17, 2022

Reactivity-informed design, synthesis, and Michael addition kinetics of C-ring andrographolide analogs

Here, based on the identification of androgapholide as a potential therapeutic treatment against cancer, Alzheimer's disease, diabetes, and multiple sclerosis, due to its ability to inhibit a signaling pathway in immune system function, the authors sought ways to optimize the natural product human systems by manipulating its chemical structure. Through the semisynthesis of a natural product along with computational studies, the authors developed an understanding of the kinetic mechanisms of andrographolide and semisynthetic analogs in the context of Michael additions.

Read More...

Herbal Extracts Alter Amyloid Beta Levels in SH-SY5Y Neuroblastoma Cells

Xu et al. | Feb 25, 2020

Herbal Extracts Alter Amyloid Beta Levels in SH-SY5Y Neuroblastoma Cells

Alzheimer’s disease (AD) is a type of dementia that affects more than 5.5 million Americans, and there are no approved treatments that can delay the advancement of the disease. In this work, Xu and Mitchell test the effects of various herbal extracts (bugleweed, hops, sassafras, and white camphor) on Aβ1-40 peptide levels in human neuroblastoma cells. Their results suggest that bugleweed may have the potential to reduce Aβ1-40 levels through its anti-inflammatory properties.

Read More...

Evaluating Biomarkers and Treatments for Acute Kidney Injury in a Zebrafish Model

Mathew et al. | Aug 11, 2019

Evaluating Biomarkers and Treatments for Acute Kidney Injury in a Zebrafish Model

Coronary Artery Disease (CAD) is the leading cause of death in the United States, and 81% of Acute Kidney Injury (AKI) patients in the renal fibrosis stage later develop CAD. In this study, Mathew and Joykutty aimed to create a cost-effective strategy to treat AKI and thus prevent CAD using a model of the zebrafish, Danio rerio. They first tested whether AKI is induced in Danio rerio upon exposure to environmental toxins, then evaluated nitrotyrosine as an early biomarker for toxin-induced AKI. Finally, they evaluated 4 treatments of renal fibrosis, the last stage of AKI, and found that the compound SB431542 was the most effective treatment (reduced fibrosis by 99.97%). Their approach to treating AKI patients, and potentially prevent CAD, is economically feasible for translation into the clinic in both developing and developed countries.

Read More...

Effect of environment factors on the expression of soluble PDE8A1 in E. coli

Jiang et al. | Oct 25, 2022

Effect of environment factors on the expression of soluble PDE8A1 in <em>E. coli</em>

PDE8, a type of phosphodiesterase (PDE), is proven to be crucial in various cellular activities and physiological activities by influencing second messenger systems. It is involved in a wide range of diseases, including Alzheimer’s disease and various heart diseases. However, there is limited information about PDE8 selective inhibitors. This work aimed to improve the solubility and yield of PDE8 in the supernatant by exploring suitable culture conditions, including temperatures and different additives.

Read More...

Assessing CDK5 as a Nanomotor for Chemotactic Drug Delivery

Jiang et al. | Sep 08, 2022

Assessing CDK5 as a Nanomotor for Chemotactic Drug Delivery

Enzyme chemotaxis is a thermodynamic phenomenon in which enzymes move along a substrate concentration gradient towards regions with higher substrate concentrations and can be used to steer nanovehicles towards targets along natural substrate concentrations. In patients with Alzheimer’s disease, a gradient of tau protein forms in the bloodstream. Tau protein is a substrate of the enzyme CDK5, which catalyzes the phosphorylation of tau protein and can travel using chemotaxis along tau protein gradients to increasing concentrations of tau and amyloid-beta proteins. The authors hypothesized that CDK5 would be able to overcome these barriers of Brownian motion and developed a quantitative model using Michaelis-Menten kinetics to define the necessary parameters to confirm and characterize CDK5’s chemotactic behavior to establish its utility in drug delivery and other applications.

Read More...

Search Articles

Search articles by title, author name, or tags

Clear all filters

Popular Tags

Browse by school level